Chinese femtech startup Micro Inno (微新医疗), a Hangzhou-based provider of intelligent solutions for women’s health, has raised eight-figure RMB (multi-million USD) in Series A+ round funding. The round was co-led by Chuanggu Capital, Hefei Industry Investment, and Guoyuan Equity.
The new funds will be used to build a medical device platform for women’s health and to accelerate product development and commercialization. Micro Inno was founded in 2021.
The company focuses on the full “screen–diagnose–treat–rehabilitate” pathway in women’s reproductive health. Its core product, Weixin Mirror, is described as the world’s smallest portable gynecological imaging device and the first globally to integrate an advanced remote gynecological imaging platform with high-quality cloud resources.
Weixin Mirror enables high-resolution, magnified, digital recording of the cervix, vagina, and external genitalia, aiming to deliver more precise clinical examinations. The device offers high resolution, “no blind spot” examinations, AI-assisted staining imaging, and remote diagnostic capabilities, and has already obtained CE certification.
According to the company, Weixin Mirror delivers diagnostic performance comparable to traditional colposcopy, while reducing overtreatment rates by around 15% and referral rates by approximately 10%. In cervical cancer screening, the device is positioned as a complement to HPV and TCT tests, helping to improve HSIL detection rates at lower cost and with better suitability for primary care settings.
With the new funding, Micro Inno plans to build an integrated platform that combines diagnosis, treatment, and rehabilitation, and to accelerate the development and launch of multiple new devices. “Our new platform will significantly reduce the operational burden on physicians, improve the efficiency of women’s disease diagnosis and treatment, and provide patients with more precise, convenient, full-cycle health solutions,” said Zhang Yang, CEO of Micro Inno.
Hefei Industry Investment’s participation as a leading state-backed investor is seen as a signal that women’s health is moving from a “niche topic” to a strategic investment theme in China. “Compared with other medical sub-sectors, the development of gynecological diagnostic and treatment devices has been relatively slow, and clinical needs have long been underestimated on both the physician and patient sides,” the firm commented. “Women’s reproductive diseases are highly prevalent, yet existing care pathways are often lengthy and inefficient, revealing significant room for market growth and quality improvement.”
